AMAL Therapeutics raises €8m
Swiss cancer vaccine developer AMAL Therapeutics has raised €8m in a Series B round led by existing investor Boehringer Ingelheim Venture Fund, and new investors BioMedPartners and Helsinn Investment Fund.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2185 entries already.
Entries by Thomas Gabrielczyk
EU states fuel antimicrobial R&D with €56.5m
Six European states, together with the Wellcome Trust, and South Africa have pledged €56.5m to help develop new antibiotics that break resistance.
Smartwatch for patient monitoring
Researchers at the University of Sussex have invented a new algorithm that could revolutionise patient monitoring and activity tracking.
EFSA okays GM bacteria as feed supplement
French Ajinomoto Eurolysine SAS, part of the world leading producer of amino acids by fermentation, has received a positive safety assessment from the European Food Safety Authority (EFSA) for use of freeze-dried genetically modified E. coli bacteria as a feedstuff supplement.
CAR-T: Novartis prices CTL019 at US$475,000
Swiss Novartis AG has received US market authorisation for its first-in-class CAR-T cell therapy Kymriah (tisagenlecleucel-T). As severe cytokine storms seemed to be generally linked to CAR-T therapies such as Kymriah, the FDA also authorised Roche’s anti-IL-6R antibody Actemra (tocilizumab) as first-in-class treatment to manage them.
FDA approves Boehringer’s biosimilar adalimumab
The US Food and Drug Administration has granted US market authorisation to Boehringer Ingelheim’s biosimilar anti-TNFa-antibody adalimumab.
Apeiron bags €25m from EIB
Supported by the European Fund for Strategic Investments (EFSI), the European Investment Bank (EIB) has granted a €25m loan to the Austrian pediatric cancer specialist Apeiron Biologics AG to boost its pipeline of antibodies, fusion proteins and low molecular weight checkpoint inhibitors.
Implementation of EU Unitary Patent Court delaying
In mid-June, the German Federal Constitutional Court asked the German President not to sign legislation designed to implement the EU Unified Patent Court (UPC, EU Agreement 16351/12) and Unitary Patent (EU Regulation 1257/12). Now, there are hints for a further delay. The constitutional complaint behind the delay, rumoured to be brought up by a German life sciences IP expert, has led to a stop of hiring German judges for the UPC.
Daratumumab meets endpoint as first-line multiple myeloma therapy
Danish Genmab A/S’ anti-CD38 antibody daratumumab has met the endpoint of progression-free survival in an interim analysis of Genmab’s pivotal Phase III study aimed at receiving FDA approval as first-line therapy in multiple myeloma.
Macrophage Pharma backed by Merck Ventures
Merck Ventures has joined the Series A investor syndicate of the British immuno-oncology specialist Macrophage Pharma Ltd.